VIRX - Viracta Therapeutics to Present at Upcoming Investor Conferences
PR Newswire
SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present and host one-on-one meetings at the following upcoming investor conferences:
| Credit Suisse 30 th Annual Healthcare Conference (virtual) |
| Conference Dates: |
| November 8 – 12, 2021 |
| Presentation Date: |
| November 11, 2021 |
| Presentation Time: |
| 1:50 PM ET |
| Format: |
| Corporate presentation |
| Jefferies London Healthcare Conference (in-person) |
| Conference Dates: |
| November 16 – 17, 2021 |
| Presentation Date: |
| November 17, 2021 |
| Presentation Time: |
| 10:40 AM GMT/ 5:40 AM ET |
| Format: |
| Corporate presentation |
| Piper Sandler 33 rd Annual Healthcare Conference (virtual) |
| Conference Dates: |
| November 29 – December 2, 2021 |
| Presentation Available: |
| November 22, 2021, at 10:00 AM ET |
| Format: |
| Corporate presentation |
| Evercore ISI 4 th Annual HealthCONx Conference (virtual) |
| Conference Dates: |
| November 29 – December 2, 2021 |
| Presentation Date: |
| December 2, 2021 |
| Presentation Time: |
| 3:55 PM ET |
| Format: |
| Fireside chat |
A live webcast of each of the presentations will be available under "Events and Webcasts" in the Investors section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts . Replays of each webcast will be archived on the Viracta website for at least 30 days following the presentation.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive (EBV + ) lymphoma and one Phase 1b /2 trial in patients with EBV + nasopharyngeal carcinoma and other EBV + solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers. For additional information please visit www.viracta.com .
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations and Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com
SOURCE Viracta
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.